Neurocrine Biosciences: Morgan Stanley raises PT to $163 from $158 to Overweight.

Neurocrine Biosciences: Morgan Stanley raises PT to $163 from $158 to Overweight.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a neuroscience-focused biopharmaceutical company, has seen its price target raised by Morgan Stanley to $163 from $158, with the investment bank upgrading its rating to Overweight. The move comes amidst strong performance and a robust pipeline of therapeutic candidates, particularly for neurological, neuroendocrine, and neuropsychiatric disorders.

According to the latest information from the company's presentation at the Cantor Global Healthcare Conference 2025, Neurocrine Biosciences has been experiencing significant growth, especially with its flagship product, INGREZZA. The company expects $2.5 billion in sales for INGREZZA in 2025, driven by strong patient starts and the successful launch of its new medication, CRENESSITY, which is the first new medicine in over 70 years for patients with congenital adrenal hyperplasia.

The company also highlighted its Phase III programs for osavampator in major depressive disorder and its muscarinic program for schizophrenia and bipolar mania, both of which are showing promising progress. These initiatives, combined with the company's strong financial position and flexibility for future investments, have contributed to the positive outlook from Morgan Stanley.

The investment bank's upgrade reflects its confidence in Neurocrine Biosciences' ability to capitalize on market opportunities and maintain its momentum. The company's strategic approach to contracting and formulary coverage, particularly for INGREZZA, has been instrumental in driving growth and reducing barriers to patient access.

References:
[1] https://www.marketscreener.com/news/rbc-raises-price-target-on-neurocrine-biosciences-to-149-from-144-keeps-outperform-rating-ce7d59d9d88ef42d
[2] https://seekingalpha.com/article/4819113-neurocrine-biosciences-inc-nbix-presents-at-cantor-global-healthcare-conference-2025